Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease
This study is currently recruiting participants.
Study NCT00831467   Information provided by CureVac GmbH
First Received: January 27, 2009   Last Updated: November 12, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hormonal Refractory Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
CV9103
Sponsors listed in this trial
CureVac GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services